Cancer clinical trials in the region Île-de-France

729 currently recruiting clinical trials
Region Île-de-France
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT07359820 #2025-523923-22-00
Required histologic sub types
Hepatocellular carcinoma Hepatocholangiocarcinoma Ampullary carcinoma
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Elevar Therapeutics
Phase 2 Lymphoma Brain tumors / Central nervous system tumors #NCT07015242 #2025-521144-38-00
Required histologic types
B cell lymphoma Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma Primary CNS lymphoma
Required central nervous system lesions
Actives
Required number of previous lines of therapy
None
Excluded previous treatments
Car-T Allogeneic stem cell transplant
12 recruiting sites
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Lung cancer #NCT04919811 #2024-516604-41-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ROS-1
10 recruiting sites
Thérapeutique AnHeart Inc
Phase 2 Endometrial cancer Sarcoma and GIST #NCT03624244
Required histologic types
Soft tissue sarcoma
Required histologic sub types
Other
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
19 recruiting sites
Centre Léon Bérard
Phase 2 Pancreas cancer #NCT07483983 #2025-522533-54-00
Cohorte pancréas
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12D
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07209111 #2025-521737-91-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 2 Lung cancer #NCT07360743 #2025-522655-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
1 recruiting site
UNICANCER
Phase 2 Multiple myeloma #NCT06931704
Required histologic types
Symptomatic multiple myeloma
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Autologous stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Hôpital universitaire de Nantes
Phase 2 Stomach and esophageal cancer #NCT06059495
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Radiotherapy
11 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2 Lung cancer #NCT06712316 #2024-515764-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Targeted therapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy Bispecific T-cell engager antibodies
24 recruiting sites
BioNTech SE